1 Quantitative insights into effects of intrapartum antibiotics and birth mode on 2 infant gut microbiota in relation to well-being during the first year of life 3 4 Birth interventions and infant gut microbiota 5 Katri Korpela<sup>a\*</sup>, Roosa Jokela<sup>a\*</sup>, Ching Jian<sup>a</sup>, Evgenia Dikareva<sup>a</sup>, Anne Nikkonen<sup>b</sup>, 6 Terhi Saisto<sup>c</sup>, Kirsi Skogberg<sup>d</sup>, Willem M. de Vos<sup>a,e</sup>, \*Kaija-Leena Kolho<sup>b,f</sup> and Anne 7 Salonen<sup>a#</sup> 8 9 10 <sup>a</sup>Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland: bChildren's Hospital, Pediatric Research Center, University of 11 12 Helsinki, Helsinki, Finland; <sup>c</sup>Department of Obstetrics and Gynecology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland; <sup>d</sup>Clinic of Infectious 13 14 Diseases, Jorvi and Helsinki University Hospital, Helsinki, Finland; <sup>e</sup>Laboratory of Microbiology, Wageningen University, Wageningen, the Netherlands; <sup>f</sup>Tampere 15 16 University, Tampere, Finland 17 \*These authors contributed equally to this work 18 19 This research was supported by grants from Tekes 329/31/2015 (Health and the Early 20 Life Microbiome (WMdV), Academy of Finland 1297765 (KK) and 1325103 (AS), 21 Pediatric Research Foundation, Finland and Helsinki University Hospital Grant (KLK), 22 The Paulo and Sohlberg Foundations (AS) and the Doctoral Program in Microbiology 23 and Biotechnology, University of Helsinki, Finland funding (RJ). 24 25 Abbreviations:

29 CRP C-reactive protein

Akaike information criterion

Analysis of variance

Cephalosporin

26

27

28

**AIC** 

Cep

ANOVA

30	CS	C-section, Caesarean section			
31	GBS	Group B Streptococcus			
32	GI	Gastrointestinal			
33	HELMi	Finnish Health and Early Life Microbiota			
34	HMO	Human milk oligosaccharide			
35	IP	Intrapartum			
36	NGS	Next generation sequencing			
37	PCoA	Principal coordinate analysis			
38	Pen	Penicillin			
39	rRNA	Ribosomal ribonucleic acid			
40	SCFA	Short-chain fatty acids			
41	VAS	Visual analogue scale			
42	VD	Vaginal delivery			
43	qPCR	Quantitative polymerase chain reaction			
44					
45					
46	#Corresponding author: anne.salonen@helsinki.fi, Haartmaninkatu 3, PO box 21, FI-				
47	00014, University of Helsinki, Helsinki, Finland				
48					
49	The authors h	ave no conflicts to declare			
50	Contributions				
51	Conceptualization: KS, KLK, AS, WMdV				
52	Data curation: AN, RJ, ED				
53	Formal Analysis: KK, RJ, CJ				
54	Funding acquisition: WMdV, AS, KK, KLK				
55	Investigation: ED, CJ, RJ, KK				
56	Methodology: KK				
57	Project admir	nistration: AS, TS, KLK, WMdV			
58	Resources: A	S, WMdV, TS, KLK			
59	Software: KK	C, CJ, RJ			
60	Supervision: AS, WMdV, KLK, KK				
61	Validation: R	J, CJ, KK			

62 Visualization: RJ, CJ, KK

- 63 Writing original draft: RJ, KK, AS
- 64 Writing review & editing: RJ, CJ, KK, KLK, WMdV, AS
- The sequencing data will be deposited upon acceptance of the article to European
- 66 nucleotide Archive.

67

**Abstract** 

69

70 71

77

86

94 95

99

102103

104

105

109 110

## **Background and aims**

- 72 Caesarean section (CS)-birth and maternally administered intrapartum antibiotics (IP)
- affect colonization of the neonate. We compared the effects of CS delivery and IP
- antibiotics on infant gut microbiota development and wellbeing over the first year. To
- 75 understand the developing community dynamics, we focused on absolute bacterial
- abundance estimates over relative abundances.

### Methods

- We studied 144 healthy infants born between gestational weeks 37-42 vaginally without
- antibiotics (N=58), with IP penicillin (N=25) or cephalosporin (N=13), or by CS with IP
- 80 cephalosporin (N=34) or other antibiotics (N=14). Gut microbiota composition and
- 81 temporal development was analysed at 5-7 time points during the first year of life using
- 82 16S rRNA gene amplicon sequencing, complemented with qPCR to obtain absolute
- 83 abundance estimates in 92 infants. A mediation analysis was carried out to identify taxa
- 84 linked to gastrointestinal function and discomfort (crying, defecation frequency and
- signs of gastrointestinal symptoms) and birth interventions.

## Results

- 87 Based on absolute abundance estimates, depletion of *Bacteroides* spp. was specific to
- 88 CS birth while decreased bifidobacteria and increased Bacilli were common to CS birth
- 89 and exposure to IP antibiotics in vaginal delivery. Abundance of numerous taxa differed
- between the birth modes among cephalosporin-exposed infants. Penicillin had a milder
- 91 impact on the infant gut microbiota than cephalosporin. The effects of both CS birth and
- 92 IP antibiotics on infant gut microbiota associated with increased gastrointestinal
- 93 symptoms during the first months.

#### Conclusion

- 96 CS birth and maternal IP antibiotics have both specific and overlapping effects on infant
- 97 gut microbiota development. The resulting microbiota deviations were found to
- associate with gastrointestinal symptoms in infancy.
- 100 Keywords: Early-life microbiota; antibiotics; caesarean section; birth route; 16S rRNA
- 101 gene amplicon sequencing; quantitative microbiota profiling

# What You Need to Know:

#### **Background and Context**

- 106 Birth mode and maternal intrapartum antibiotics affect infant's gut microbiota
- 107 development but their relative contribution, and effects on absolute bacterial
- abundances and infant health remain unknown.

New Findings

- 112 Utilizing quantitative microbiota profiling, we identified shared and unique microbiota
- effects of birth mode and intrapartum antibiotics which explained up to 54% of
- variation in parent-reported gastrointestinal symptoms in infants.

### Limitations

111

115116

120 121

125

128

- Due to the limited sample sizes, especially during the first weeks of life, stratified
- analyses according to antibiotic dosing could not be performed, and the results on
- gastrointestinal symptom-microbiota-associations are tentative.

### **Impact**

- Birth mode overrules the effects of maternal antibiotics on infant microbiota
- 123 development, while both birth mode and maternal antibiotic use are associated to
- 124 common functional gastrointestinal symptoms in infancy.
- 126 Lay summary: Caesarean-section birth and maternal antibiotics during vaginal birth
- affect infant's gut microbiota and may increase gastrointestinal discomfort.

Introduction

129

130

131

132

133

134

135136

137

138139140

141

142

143

144

145

146147148

149

150

151

152153

154

155156

157

158159

160

161

The human intestinal microbiota develops via successional stages during early life. The infant's gut microbiota contributes to early immunological<sup>2</sup> and metabolic programming<sup>3</sup> that affects host health later in life.<sup>4</sup> Transmission of maternal microbes to the offspring during birth plays a major role in the initial colonization. <sup>1, 5, 6</sup> The mode of birth is a major determinant of the neonates' initial microbial exposure; the assembly and dynamics of intestinal microbiota in infants born via caesarean section (CS) versus vaginal delivery (VD) differ substantially, 1, 7 which has been suggested to mediate the negative long-term health outcomes related to CS birth. 8,9 CS birth is not the only intervention impacting the neonate's early colonisation. Intrapartum (IP) antibiotic prophylaxis is routinely administered to mothers undergoing CS to reduce the risk of post-caesarean maternal infection. In vaginal deliveries approximately 25% of the mothers receive antibiotics to prevent neonatal group B Streptococcus (GBS) infection. <sup>10</sup> Thus, antibiotics are used in a substantial number of deliveries in developed countries. Emerging evidence suggests that IP antibiotics influence the infant's microbiota development over a period of several months. 11-13 Previous studies utilizing next generation sequencing (NGS) have characterised the infant gut microbiota using relative bacterial abundance. However, quantitative analyses indicate that early microbiota development entails major quantitative changes both for the total bacterial load as well as on individual taxa, 14 and the effects of birth interventions on absolute bacterial profiles are unknown. <sup>15</sup> In addition, current studies addressing the health effects of IP on newborns have largely focused on neonatal GBS infection, 16, 17 with first reports investigating their potential long-term effects on child health. 18 We analysed the gut microbiota development in 144 healthy infants over the first year of life, focusing on 92 infants from whom qPCR- and NGS-based quantitative microbiota profiling<sup>19</sup> data for absolute abundance estimation was available. The bacterial abundances were further associated with parallelly collected gastrointestinal (GI) and general health data. This approach enabled us to bypass the compositionality problem arising from relative abundances, <sup>20</sup> which may mask true community dynamics<sup>21</sup> and lead to high false discovery rates.<sup>19, 22</sup> We controlled for potential confounding factors using a carefully selected cohort, aiming to disentangle the effect of

CS birth and IP antibiotics from potentially collinear effects.

# **Materials and Methods**

Study design

162

163

164

165

166

168

169170

171

172

173

174

175176

177

178

179

180

181

182

183184

185

186

187

188

189

190

191

192

193

167 Infants specifically recruited for this study (Jorvi cohort, N=68) and additional 83

infants recruited for the Finnish Health and Early Life Microbiota (HELMi) cohort<sup>23</sup>

(NCT03996304) were included in the study. In both cases, pregnant women with

singleton gestation were recruited from the general population in Southern Finland.

Healthy babies, born on gestational weeks 37-42, without known congenital defects and

exceeding the birth weight of 2.5 kg were included in the study (except one baby with

birth weight of 2.4kg). At least one parent had to be Finnish speaking to be able to

answer the questionnaires.

For the Jorvi cohort, 31 mothers delivered with (vaginal deliveries N=26/31) and 37 without IP antibiotics (all vaginal deliveries). Infant faecal samples were collected on day 1, 2, and 7, and at 1, 3, 6 and 12 months. From the HELMi cohort, 83 infants were selected based on birth mode, IP antibiotics, and the availability of sequencing data from infant's faecal samples at the age of 3 (considered as 1 month sample), and 6 weeks, and 3, 6, 9, and 12 months. From the combined cohort, five infants were excluded as they received post-natal antibiotics prior to the first sampling point, and two infants were excluded for low sequence quality, leaving a total of 144 infants. Additionally, all samples following a post-natal antibiotic treatment were excluded from the analysis as well as individual samples with low sequence quality (see Statistical analysis). We divided the remaining infants into five study groups based on birth mode and IP antibiotics: vaginally delivered (VD) reference group without IP antibiotics (N=58), and four exposure groups: cefuroxime or cephalexin (cep) in CS (N=34), or in VD (N=13), penicillin (pen) in VD (N=25), or in CS penicillin or any other antibiotics, a combination of antibiotics or the antibiotic class not reported (CS-other, N=14) (Table 1). The CS groups comprised elective (N=23) and urgent (N=25) cases; all involved IP antibiotics. Based on sample sufficiency, birth mode and sampling point the samples from 92 infants were quantified for total bacteria by qPCR, <sup>19</sup> representing 26 infants in

195

196 197

198

199

200201

202

203

204

205

206

207

208

209210

211

212

213

214

215

216

217

218

219220221

222

223

224

225

226

the reference group VD, 7 in VD-cep, 13 in VD pen, 33 in CS-cep, and 13 in CS-other group. Both cohort studies were approved by the ethical committee of The Hospital District of Helsinki and Uusimaa and performed in accordance with the principles of the Helsinki Declaration. Parents signed an informed consent at enrolment. Samples and data collection Parents collected faecal samples from the infants and stored them at -20°C. The samples were transported frozen to the study centre within 6 months for -80°C storage. Data on feeding regime, probiotic and antibiotic use, child health and growth were collected with questionnaires (HELMi) or via phone interviews from the parents at the times of stool sampling (Jorvi). Data on exposures i.e., the mode of delivery and the usage, type and dosing of maternal IP antibiotics were collected from hospital records for both cohorts. **Health outcomes** Infant health and wellbeing were addressed using questionnaire data available for the HELMi cohort. We used data from weekly to monthly repeating questionnaires using the questionnaire closest to each faecal sampling. The variables included were related to crying (hours per day and intensity estimated by a 0-100 mm visual analogue scale (VAS), collected until six months, GI function (defecation rate, parent-perceived stomach pain intensity and flatulence) until 9 months, and frequency of infections estimated by the number of post-natal antibiotic courses by age of 12 months. Infant growth was measured in postnatal care visits and transformed to age-dependent WHO z-scores.<sup>24</sup> Microbiota profiling Bacterial DNA was extracted from the faecal samples using a previously described bead beating method<sup>25</sup> and KingFisherTM Flex automated purification system (ThermoFisher Scientific, USA) as detailed in Supplementary methods. 16S rRNA gene amplicon sequencing was performed using Illumina MiSeq and HiSeq platforms for

V3-V4 or V3 region as previously described, 19, 26 respectively. In case of low DNA

228

229

230

231232

233

234

235

236

237

238239

240

241

242243

244

245246247248

249

250

251

252

253

254

255256

257

258

yield or unsuccessful sequencing, the default library preparation protocol was modified as specified in Supplementary methods. The numeration of total bacteria was performed in triplicate as previously described. <sup>19</sup> Bacterial DNA was quantified by amplifying 0.5 ng aliquots of each DNA extract with universal bacterial primers 331F/797R<sup>27</sup> targeting the 16S rRNA gene. The standard curves ranging from 10<sup>2</sup> to 10<sup>7</sup> copies were constructed using the full-length amplicons of 16S rRNA gene of Bifidobacterium bifidum to convert the threshold cycle (Ct) values into 16S rRNA gene copy numbers per g of faeces. The sequencing reads were processed using R package mare, 28 which relies on USEARCH<sup>29</sup> for quality filtering, chimera detection, and taxonomic annotation. Only the forward reads (V3), truncated to 150 bases, were used. <sup>30</sup> Reads occurring <10-50 times, depending on run size, were excluded as potentially erroneous. Taxonomic annotation was performed using USEARCH<sup>29</sup> by mapping the reads to the SILVA 16S rRNA reference database version 115,31 restricted to gut-associated taxa. Further, potential contaminants in the low-DNA-yield samples were filtered by removing reads appearing in negative controls (PCR or extraction blanks) in corresponding numbers from all samples. The absolute abundances were estimated and 16S rRNA gene copynumber corrected as previously described. 19 Statistical analysis After processing, the median number of reads obtained was 26 384 (range 3 to 253 458). Sufficient sequencing coverage was evaluated by comparing observed species richness to read count, and a cut-off of 2000 reads was chosen for HELMi samples, and 120 for Jorvi samples (to accommodate low-biomass samples from the first week of life). Samples with insufficient coverage (N=138, largely samples from the first week of life) and 69 samples with extremely high read counts from a single HiSeq run with high proportions of probable contaminants (mostly *Alcaligenaceae*)<sup>32</sup> were excluded, leaving a total of 688 high-quality samples from 144 infants for downstream analyses, and 393 high-quality qPCR quantified samples from 92 infants.

260261

262

263

264

265266

267268

269

270

271

272

273

274

275

276

277

278

279

280

281282283

284285

286

287

288

289290

291

The statistical analysis was conducted in R version 3.6.3 with the package mare, <sup>28</sup> with tools from packages vegan, 33 MASS, 34 and nlme 35, detailed in Supplementary methods. The association of antibiotic exposure (no antibiotic, penicillin, cephalosporin) and birth mode (vaginal or CS) with health outcomes was analysed at each faecal sampling until 9 months using a negative binomial model adjusting for feeding type and probiotic use. To determine if the differences in health outcomes were mediated by changes in gut microbiota, the *PathModel* function in mare<sup>28</sup> was used to identify taxa predicting symptoms and the role of birth interventions related to the predictive taxa. **Results Study population** An average of 4.9 samples (range 1-7) was collected per infant (Table 1) from the 144 infants born by VD (N=96) or CS (N=48) during the first12 months. The urgent and elective CSs were pooled for analysis (Supplementary results, Supplementary Figure 1). The IP antibiotics and doses varied among the delivery modes, with cefuroxime being the most common antibiotic used in CS and penicillin in VD (Table 2). Of all the VD antibiotics, 74% were solely prophylactic, of which 93% to prevent GBS transmission, and 7% due to premature rupture of membranes, while 69% of cephalosporins were therapeutic. Therapeutic IP antibiotics were administered due to fever or a rise in Creactive protein (CRP) of the mother. Absolute bacterial profiles were calculated for a subset of 92 infants (VD: N=46, CS: N=46). Infant background statistics are summarised in Supplementary Table 1. The early development of the gut microbiota from birth to 12 months of age Birth mode or antibiotic exposure did not influence the total bacterial abundance quantified by qPCR at any given sampling time (P>0.05). Overall, the bacterial load increased with infant age in all groups, especially during the first weeks (Supplementary Figure 2). To understand the temporal dynamics of the gut microbiota in infants, we analysed the average developmental trajectory of the 6 most abundant bacterial classes in infants

293

294

295

296297

298

299

300

301302

303

304

305306

307

308

309

310

311

312

313

314315

316

317

318

319

320321

322

323

324

born by VD without antibiotics, comparing their relative (day 1 onwards) and absolute abundances (day 2 onwards) (Figure 1). Relative abundances show different community dynamics, such as a gradual decrease in the relative abundance of Enterobacteriales instead of the peak in absolute abundance around 20 weeks of age (Figure 1). The overall developmental trajectories of the microbiota differed between the study groups categorized by delivery mode and antibiotic type (Table 1) in the ordination space using principal coordinate analysis (PCoA) (Figure 2). The temporal development of the gut microbiota followed a discernible pattern in the reference group (VD without antibiotics), and each exposure group showed a distinct developmental trajectory based on both absolute (Figure 2A) and relative data (Figure 2B). By 24 weeks, all but VDcep converged with the reference group. The temporal trajectory of the gut microbiota in the VD-cep group markedly deviated from the reference group (Figure 2). Impact of birth mode and intrapartum antibiotic on the temporal development of the gut microbiota using absolute data To better understand the developing community dynamics, from this onwards we focused on the absolute abundance data. We first compared abundances of bacterial families and genera of the exposure groups to the reference (VD without antibiotic), adjusting for breastfeeding, probiotics, and the introduction of solids when relevant. The results observed at family level (Figure 3) were largely consistent at the genus level (Supplementary Figure 3). In the first 3 months, the absolute abundance of *Bacteroidaceae* was significantly reduced in the CS, but not in the antibiotic-VD groups (fold change range 0.010-0.11, P<0.01 Figure 3). The depletion of *Bacteroidaceae* became statistically significant later, at 6 months and 9 months, in VD-cep (fold change 0.014, P=0.0003) and VD-pen (fold change 0.030, P=0.01). Coriobacteriaceae (Actinobacteria) followed a pattern similar to that of Bacteroidaceae, being mainly associated with birth mode. The absolute abundance of Bifidobacteriaceae was strongly and negatively affected by both CS birth and by both cephalosporin and penicillin at 1 month, (fold change range 0.0040-0.18, P<0.01,

Figure 3) compared to VD without antibiotics. *Actinomycetaceae* and *Micrococcaceae* were enriched in all the exposure groups except the VD-pen group at one month (fold change range 6.2-13, *P*<0.001, Figure 3). Families in the Bacilli class, *Staphylococcaceae, Enterococcaceae, Lactobacillaceae*, and *Streptococcaceae*, were increased in absolute abundance in all exposure groups during the first 3 months (fold change range 1.0-240, *P*<0.05, Figure 3). The absolute abundances of several families in the classes Clostridia and Negativicutes were increased in all the exposure groups during the first month in comparison to the reference, with a few exceptions: reduced *Christensenellaceae* in the CS-other group at 1 month and in both CS groups at 6 weeks, reduced *Ruminococcaceae* in all but the VD-pen group at 1 and 3 months, and reduced *Acidaminococcaceae* in the CS groups at 4-6 weeks (Figure 3). The absolute abundances of Proteobacterial families in the antibiotic-exposed groups significantly deviated from the reference at multiple time points (fold change range 0.00054-6100, *P*<0.05, Figure 3).

# Dissecting the effects of birth mode and intrapartum antibiotic on absolute levels

### of infant microbiota

We compared the birth modes while controlling for the IP antibiotic exposure, including only the cephalosporin-exposed CS and VD, to understand the effect of birth mode independently of antibiotic treatment, and *vice versa* (including only the vaginally born) (Supplementary Figures 4, 5). Several bacterial families differed in absolute abundance between the VD-cep and CS-cep groups, including enrichment of *Verrucomicrobiaceae* (3.8-fold difference, *P*<0.001 at 6 weeks), *Bifidobacteriaceae* (18 and 12-fold differences, *P*<0.05 at 1 and 3 months, respectively), *Streptomycetaceae* (7.0 and 62-fold differences, *P*<0.001 at 1 month and 9 months), *Lactobacillaceae* (8.3 and 12-fold differences, *P*<0.05 at 3 and 9 months), *Bacillaceae* (3.8 and 8.5-fold differences, *P*<0.001 at 6 weeks and 6 months), *Peptostreptococcaceae* (fold change range 7.5-5900, *P*<0.01 at 1, 3 and 6 months), *Lachnospiraceae* (20 and 99-fold differences, *P*<0.01 at 3 and 6 months), *Clostridiaceae* (23-fold difference, *P*<0.001 at 1 month), and *Christensenellaceae* (210-fold difference, *P*<0.001 at 6 months) in the CS-cep group. In contrast, *Bacteroidaceae* was reduced in CS-cep in comparison to VD-cep during months 1-3 (fold change 0.07, *P*<0.01 at 6 weeks).

In terms of the effect of antibiotic types in the vaginally born infants, increased absolute abundances were found in *Verrucomicrobiaceae* and *Rikenellaceae* (22 and 79-fold differences, *P*<0.001 at 6 weeks), *Bifidobacteriaceae* and *Lactobacillaceae* (25 and 5.2-fold differences, *P*<0.01 at 3 months), *Coriobacteriaceae* (fold change range 6.0-910, *P*<0.001 at 1-3 months), *Peptostreptococcaceae* (94 and 72-fold differences, *P*<0.05 at 1 and 6 months), *Christensenellaceae* (8300-fold difference, *P*<0.001 at 6 months), *Bacillaceae* (36 and 13-fold differences, *P*<0.001 at 6 weeks and 6 months) in the VD-cep group compared to VD-pen. Members of *Clostridiaceae* were consistently reduced

in VD-pen in comparison to VD-cep at 1 month (fold change 0.34, *P*<0.001).

# **Health outcomes**

To determine whether the mode of delivery and IP antibiotics were associated with the infants' health during the first year of life, we compared the study groups in terms of health variables from the HELMi questionnaires pertinent to parent-reported digestive and overall health (Figure 4). All exposure groups showed increased GI symptoms mainly during the first 3 months compared to the reference group VD. There were significant differences in defecation rate, crying intensity, duration of crying per day, parent-perceived stomach pain intensity, and flatulence between the study groups (Figure 4). Infants' overall health as reported by the parents did not differ between the study groups at any sampling age (ANOVA: P>0.1), nor did the cumulative number of antibiotic courses by 12 months (P=0.81) nor infant weights at birth or at 12 months (ANOVA,  $P\geq0.25$ , Supplementary Table 1).

## Week 4

We assessed the hypothesis that the differences in the gut microbiota mediate the GI symptoms by performing a mediation analysis on the symptoms at time points that showed significant differences between the study groups (Figure 4) in infants with absolute data available (Supplementary Table 2). We analysed the association between antibiotic exposure and birth mode as separate variables with the health outcomes, compared the study groups in terms of the health outcomes, and identified bacterial taxa associated with both the health outcomes and the antibiotic exposure or birth mode. At 4 weeks, cephalosporin exposure (including both vaginal birth and CS) was significantly and positively associated with crying intensity (*P*=0.009), and when comparing groups,

the VD-cep group had increased crying intensity in comparison to the reference group (P=0.009). A model using absolute bacterial abundances explained 24% of the variation in crying intensity (Figure 5a). The association of cephalosporin exposure with crying intensity appeared to be mediated by the low abundance of *Bacteroides* associated with cephalosporin exposure. Defectation rate was positively associated with cephalosporin exposure (P<0.0001) and CS (P<0.0001), and the CS-cep group had elevated defectation rate (P<0.0001) compared to the reference group. The bacterial composition explained 28% of the variation in defectation rate. The increased defectation rate in the CS-born and cephalosporin-exposed infants compared to the controls appeared attributable to the decreased abundances of *Bacteroides* and uncultured *Veillonellaceae* (Figure 5a).

#### Week 6

At 6 weeks, defecation rate was elevated in the CS-cep group (P=0.007) compared to the reference, and both CS birth (P=0.006) and cephalosporin exposure (P=0.01) were independently associated with increased defecation rate. The gut microbiota composition was associated with defecation rate, explaining 51% of the variation. The effects of CS birth and cephalosporin appeared to be mediated by the decreased abundances of *Bifidobacterium* and *Finegoldia* (Figure 5b). Stomach pain intensity was significantly elevated in the CS-cep (P=0.009) and VD-cep (P=0.01) groups compared to the reference. Cephalosporin exposure was significantly associated with stomach pain (P=0.005). The association was mediated by the reduced abundance of *Collinsella* and the increased abundances of *Escherichia* and *Streptococcus* in the CS-born and cepexposed infants (Figure 5b). Gut microbiota composition explained 30% of the variation in stomach pain intensity.

### Week 12

- At 12 weeks, stomach pain intensity was increased in the CS-cep group (P=0.04) and
- 418 VD-cep group (P=0.02) compared to the reference. Cephalosporin exposure was
- 419 significantly associated with the pain intensity (P=0.02). The gut microbiota explained
- 420 46% of the variation in stomach pain, the low absolute abundance of *Alistipes* and high
- 421 abundance of *Roseburia* being linked with both CS birth and stomach pain (Figure 5c).
- 422 Flatulence intensity was increased in the CS-cep group (P=0.02) compared to the
- reference, and CS birth (P=0.05) and cephalosporin exposure (P=0.02) were associated

425

426

427

428 429

430431

432

433

434

435

436

437

438

439

440

441442

443

444

445

446

447

448

449450

451

452

453

454455

456

with increased flatulence intensity. The gut microbiota explained 23% of the variation in flatulence intensity at 12 weeks. The association of CS birth and cephalosporin and flatulence appeared mediated by the reduced abundance of Bacteroides and Alistipes (Figure 5c). Week 24 At 24 weeks, stomach pain intensity was associated with penicillin exposure (P=0.01) and increased in the VD-pen group (P=0.01) compared to the reference. Gut microbiota composition explained 54% of the variation in stomach pain intensity, with Paludibacter mediating the association with penicillin exposure (Figure 5d). **Discussion** We set out to study how the temporal quantitative and compositional gut microbiota development is influenced by the mode of delivery versus exposure to delivery antibiotics, and whether these early exposures and associated differences in early microbiota composition relate to common gastrointestinal symptoms in Whereas CS delivery had profound effects on the gut microbiota, we observed that maternal IP antibiotics compromised the colonisation of the newborn's gut microbiota independent of the birth mode. Notably, the decreased absolute abundance of Bifidobacterium and increased abundance of Bacilli characterised both CS-deliveries and IP antibiotic exposed vaginally delivered infants, whereas reduction of *Bacteroides* was mainly seen after CS delivery. Moreover, we observed that the changes in gut microbiota taxa associated to CS birth and IP antibiotic exposure were further associated with increased GI symptoms. This is one of the first studies using quantitative microbiota profiling 19, 36 for community-wide absolute abundance estimates of infants' indwelling gut bacteria and the first to address the associated GI health. The vast majority of existing NGS studies on human microbiota utilize only relative abundance. This has been recently shown to under- or overestimate temporal changes of the gut microbiota in preterm infants,<sup>21</sup> especially concerning Proteobacteria such as Escherichia coli and Klebsiella. Several members within Proteobacteria, such as E. coli, possess flexible metabolic capacity<sup>37</sup> and fast replication rate and therefore have high temporal variation in cell density. In the

458

459

460

461

462

463

464

465

466467

468469

470

471

472

473

474

475

476

477478

479

480

481

482

483

484

485

486 487

488

489

present study, we documented a decreasing developmental trajectory of the most abundant Proteobacterial order Enterobacteriales in relative abundance data, in line with earlier relative abundance studies.<sup>38</sup> In contrast, the absolute abundance of Enterobacteriales increased over the first 6 months of life, peaking around the time of introducing complementary foods, in agreement with a previous study in term infants utilizing targeted qPCR.<sup>39</sup> The developmental patterns of other dominant bacteria are largely in concordance with the previous qPCR-based study, showing a general upward trend in the first few months of life. 39 Relative abundances also underestimate taxa with low 16S rRNA gene copy numbers, such as *Bifidobacteriales* (mean 3.5 copies<sup>40</sup>) compared to taxa with high copy numbers, such as *Clostridiales* (mean 5.5 copies<sup>40</sup>), observed also in this study. CS birth has been suggested to cause microbial deprivation, a lack of microbial colonisation in early life. This was not the case in our study, as CS-born and antibioticexposed infants were colonised with comparable total bacterial loads per gram of faeces as the non-exposed vaginally born group. We observed a clear age-driven increase in the bacterial loads in all study groups using qPCR. Unfortunately, majority of the low bacterial biomass samples from the first week of life had insufficient amount of faecal sample to allow quantitative analyses. Previous studies have reported lower bacterial loads in CS born infants, 41 and a faster age-driven increase in bacterial quantities in the stools of CS born infants.<sup>42</sup> It is nevertheless possible that the transient difference in total microbial load occurring before 3 weeks of age was not detected in the present study. Relative abundance studies have consistently documented an altered signature in gut microbiota of CS born infants, recently shown to be restored by maternal FMT.<sup>43</sup> Most studies on infant microbiota in relation to birth mode have neglected the fact that practically all CS births involve IP antibiotics, making it impossible to isolate the effects of IP versus the birth route. 44 Our results comparing the effect of birth mode under the exposure to the same antibiotic, cephalosporin, confirm that birth mode per se influences the infant gut microbiota. CS birth usually involves the administration of cephalosporin, while in VD, the most commonly used IP antibiotic

is penicillin. 45 It should be noted that the use of cephalosporin in VD typically indicates

therapeutic rather than prophylactic use, and in our cohort, every other cep-VD mother received multiple doses compared to the single prophylactic dose used in CS. Hence, in clinical settings, labours with different IP antibiotics may also differ for other factors than the antibiotic exposure. A recent randomized trial documented a lack of clear differences in the gut microbiota of CS-born infants exposed versus unexposed to IP antibiotic. In conclusion, our study and earlier data indicate that the mode of birth is the major factor affecting neonatal colonisation, in line with CS eliminating the contact between the infant and maternal gut bacteria, preventing their transmission at birth. Infants born by elective CS, in the absence of labour and rupture of membranes, are believed to be the most deprived from the vertically transmitted microbes. A recent study however contradicted this hypothesis, which we corroborated by showing the negligible differences in the infant microbiota between the elective and urgent CS deliveries.

In contrast, in VD infants the IP antibiotic plays a major role. We showed that the impact of IP antibiotic exposure during vaginal birth on the gut microbiota was largely similar to the effect of CS delivery on the infant gut microbiota. However, we were able to identify several distinct effects of birth mode and antibiotic exposure. Namely, the early absolute abundances of Bacteroidaceae, Coriobacteriaceae and Burkholderiaceae were reduced by CS birth but not by IP antibiotics, while Ruminococcaceae, Porphyromonadaceae, Rikenellaceae, and Pasteurellaceae abundances were negatively affected by both CS birth and antibiotics. Bifidobacteriaceae was most strongly affected by the antibiotic exposure. These observations recapitulate and expand the results of a recent Japanese study<sup>48</sup> and Canadian studies.<sup>49</sup> With absolute data, we found the effect of IP antibiotics in VD infants to peak at 3 months with some differences persisting up to 12 months. Previous studies using relative microbiota data have reported the effect of birth-related antibiotics to resolve after 3 months, 47 however, most of the studies do not extend over this age. 13 A recent prospective study on 100 vaginally born infants reported the effect of IP antibiotics to overrule those of post-natal antibiotics on the infant microbiota, and persist until the at age of one year.<sup>50</sup>

Importantly, several bacterial taxa were increased in absolute abundance in the CS-born and in the antibiotic exposed infants. For example, IP antibiotic exposure in VD, and

524

525

526527

528

529

530

531532

533

534

535

536537

538

539

540

541542

543

544

545

546

547

548

549

550

551552

553

554

555

CS birth both resulted in the overgrowth of streptococci as well as staphylococci and enterococci. This is likely due to reduced colonization resistance resulting from the depletion of bifidobacteria, which have anti-streptococcal activity. In fact, the majority of bacterial taxa affected by IP antibiotics, except bifidobacteria, were increased in absolute abundance during the first month. This suggests that the major driver of microbial changes after exposure to IP antibiotic is not the antibiotic itself, but the antibiotic-induced reduction in bifidobacteria. Since the direct effects by the IP antibiotic on the infant are short (from hours to couple of days), the lasting effects likely reflect the consequences of the fundamental alteration in the ecosystem assembly. The pattern is somewhat different after CS birth, where diverse members of the microbiota, including *Bacteroides*, bifidobacteria and members of Clostridiales and Negativicutes, were likely directly reduced due to lower mother-infant microbiota transmission rates in CS birth.

To our knowledge, our study is the first to evaluate the influence of birth mode and associated maternal antibiotic administration in parallel with the infant gut microbiota and functional GI symptoms. Previously, CS birth and postnatal antibiotics have been identified as risk factors for functional GI disorders in pre- and full-term infants.<sup>53</sup> In our study, CS-born and VD IP antibiotic-exposed infants experienced more parentreported abdominal discomfort and crying compared to VD infants with no antibiotics in the first month of life, while their general health and growth was comparable. According to the mediation analysis, the CS-associated reduction in the abundance of Bacteroides and its relatives was linked to increased defecation rates and crying intensity at 1 month, and increased flatulence and stomach pain at 3 months compared to the reference. The cephalosporin-associated decline in Bifidobacterium and Collinsella was associated with increased defecation rate and stomach pain at 6 weeks compared to the reference. Colic symptoms have previously been linked with the reduced relative abundance of bifidobacteria<sup>54, 55</sup> and to an altered balance between H<sub>2</sub>producing and -utilising taxa.<sup>56</sup> Overall, the models based on absolute bacterial abundances explained 23-54% of the infants' GI symptom variation, which is remarkable considering that the origin and underlying reasons of functional GI symptoms in infants often remain unclear.<sup>57</sup> These results are preliminary and derived from a relatively small study, and hence need validation in future cohorts.

558

559

560561

562

563

564

565566

567

568

569570

571

572

573

574

575

576577

578

579580581

582

583

584

585586

587588

Bacteroides and bifidobacteria are the major human milk oligosaccharide (HMO) degraders and thus keystone taxa in the breastfed infant gut, 58-60 so their depletion will have profound impact on the metabolic capacity and processes in the infant gut.<sup>61</sup> Reduced conversion of HMOs into short-chain fatty acids (SCFA) increases gut pH, <sup>62, 63</sup> and alters trophic interactions and metabolic outputs of the gut microbiota. Such changes likely affect gut physiology and function and may favour bacteria that normally are less abundant in the infant gut, such as members of Clostridia, which in the present study were associated with increased defecation rates, flatulence, and stomach pain. There is some uncertainty as to how long the microbiota differences persist after CS birth or IP antibiotic exposure, and how the persistence affects host physiology. Studies based on relative abundance data have shown a convergence to vaginally born controls during 6-12 months. 11,64 Long-term studies on the effects of IP antibiotic exposure have not been conducted. Our findings suggest that several birth-mode and IP antibioticrelated microbial signatures are still detectable at 12 months, although the major differences subside by 6 months. There may be individual differences regarding the normalisation of the gut microbiota after CS birth or antibiotic exposure, possibly related to diet, probiotic use, and other practices. 65, 66 A recent Danish study showed that increased asthma risk was found in children born by CS only if their gut microbiota composition at 1 year of age still retained a CS-birth-related microbial signature, 9 while animal experiments showcase that even a transient early microbiota disruption is sufficient to lead to persistent functional and even structural alterations in the immune system.<sup>67</sup> Together, CS and antibiotic exposure at birth affect a substantial proportion of infants worldwide. Our data suggest that their effects on early colonisation of the gut microbiota may cause elevated levels of pain and discomfort in the infant during the first months of life, while a recent study found no association between IP antibiotics and childhood allergies. 18 These studies are important primers for filling the knowledge gaps that underlie the lack of consensus for the choice between universal or risk-based screening for IP antibiotic use, 10 and contribute to weighing the benefits and potential harms of antibiotic use in mothers and infants.

Acknowledgements

This research was supported by grants from Tekes 329/31/2015 (Health and the Early Life Microbiome (WMdV), Academy of Finland 1297765 (KK) and 1325103 (AS), Pediatric Research Foundation, Finland and Helsinki University Hospital Grant (KLK), The Paulo and Sohlberg Foundations (AS) and the Doctoral Program in Microbiology and Biotechnology, University of Helsinki, Finland funding (RJ). We thank Tinja Kanerva for processing the samples and Jessica Manngård for assistance with the questionnaire data analysis and Tytti Jaakkola, MD for recruiting some of the patients in the Jorvi cohort.

### REFERENCES

- Korpela K, de Vos WM. Early life colonization of the human gut: microbes matter everywhere. Curr Opin Microbiol 2018;44:70-78.
- Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Allergology International 2017.
- 606 3. Cox LM, Yamanishi S, Sohn J, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014;158:705-721.
- 609 4. Cox LM, Yamanishi S, Sohn J, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014;158:705-721.
- Bäckhed F, Roswall J, Peng Y, et al. Dynamics and Stabilization of the Human
   Gut Microbiome during the First Year of Life. Cell Host Microbe 2015;17:690 703.
- 615 6. Yassour M, Jason E, Hogstrom LJ, et al. Strain-Level Analysis of Mother-to-616 Child Bacterial Transmission during the First Few Months of Life. Cell Host & 617 Microbe 2018;24:146-154.e4.
- 518 7. Shao Y, Forster SC, Tsaliki E, et al. Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth. Nature 2019;574:117-121.
- 8. Stiemsma LT, Michels KB. The Role of the Microbiome in the Developmental Origins of Health and Disease. Pediatrics 2018;141:e20172437.
- Stokholm J, Thorsen J, Blaser MJ, et al. Delivery mode and gut microbial changes correlate with an increased risk of childhood asthma. Science
   Translational Medicine 2020;12:eaax9929.
- Le Doare K, Heath PT, Plumb J, et al. Uncertainties in Screening and Prevention of Group B Streptococcus Disease. Clin Infect Dis 2019;69:720-725.
- Dierikx TH, Visser DH, Benninga MA, et al. The influence of prenatal and intrapartum antibiotics on intestinal microbiota colonisation in infants: A systematic review. Journal of Infection 2020.
- Tapiainen T, Koivusaari P, Brinkac L, et al. Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants. Sci Rep 2019;9:10635.
- Zimmermann P, Curtis N. Effect of intrapartum antibiotics on the intestinal
   microbiota of infants: a systematic review. Archives of Disease in Childhood Fetal and Neonatal Edition 2020;105:201.
- Penders J, Thijs C, Vink C, et al. Factors Influencing the Composition of the Intestinal Microbiota in Early Infancy. Pediatrics 2006;118:511.
- Jian C, Carpén N, Helve O, et al. Early-life gut microbiota and its connection to
   metabolic health in children: Perspective on ecological drivers and need for
   quantitative approach. EBioMedicine 2021;69.
- 641 16. McLaren RA, Atallah F, Minkoff H. Antibiotic Prophylaxis Trials in Obstetrics: A Call for Pediatric Collaboration. AJP Rep 2020;10:e155-e158.
- 643 17. Russell NJ, Seale AC, O'Sullivan C, et al. Risk of Early-Onset Neonatal Group 644 B Streptococcal Disease With Maternal Colonization Worldwide: Systematic 645 Review and Meta-analyses. Clinical Infectious Diseases 2017;65:S152-S159.

- Dhudasia MB, Spergel JM, Puopolo KM, et al. Intrapartum Group B
   Streptococcal Prophylaxis and Childhood Allergic Disorders. Pediatrics
   2021;147.
- Jian C, Luukkonen P, Yki-Järvinen H, et al. Quantitative PCR provides a simple and accessible method for quantitative microbiota profiling. PLOS ONE
   2020;15:e0227285.
- 52 20. Jackson DA. Compositional data in community ecology: The paradigm or peril of proportions? Ecology 1997;78:929-940.
- Rao C, Coyte KZ, Bainter W, et al. Multi-kingdom ecological drivers of microbiota assembly in preterm infants. Nature 2021;591:633-638.
- Gloor GB, Macklaim JM, Pawlowsky-Glahn V, et al. Microbiome Datasets Are Compositional: And This Is Not Optional. Frontiers in Microbiology 2017;8.
- Korpela K, Dikareva E, Hanski E, et al. Cohort profile: Finnish Health and Early Life Microbiota (HELMi) longitudinal birth cohort. BMJ Open 2019;9:e028500.
- Ebrahim GJ. WHO Child Growth Standards. Growth Velocity Based on Weight,
   Length and Head Circumference. Methods and Development. Journal of Tropical
   Pediatrics 2010;56:136-136.
- Salonen A, Nikkilä J, Jalanka-Tuovinen J, et al. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J Microbiol Methods 2010;81:127-34.
- Milani C, Hevia A, Foroni E, et al. Assessing the Fecal Microbiota: An
   Optimized Ion Torrent 16S rRNA Gene-Based Analysis Protocol. PLOS ONE
   2013;8:e68739.
- Nadkarni MA, Martin FE, Jacques NA, et al. Determination of bacterial load by
   real-time PCR using a broad-range (universal) probe and primers set.
   Microbiology (Reading) 2002;148:257-266.
- 673 28. Korpela K. mare: Microbiota Analysis in R Easily. R package version 1.0 ed, 2016.
- Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 2010;26:2460-2461.
- Korpela K, Blakstad EW, Moltu SJ, et al. Intestinal microbiota development and gestational age in preterm neonates. Scientific Reports 2018;8:2453.
- Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene database
   project: improved data processing and web-based tools. Nucleic acids research
   2013;41:D590-D596.
- Salter SJ, Cox MJ, Turek EM, et al. Reagent and laboratory contamination can
   critically impact sequence-based microbiome analyses. BMC Biology
   2014:12:87.
- Jari Oksanen FGB, Michael, Friendly, Roeland Kindt, Pierre Legendre, Dan,
   McGlinn, Peter R. Minchin, R. B. O'Hara, Gavin L., Simpson, Peter Solymos,
   M. Henry H. Stevens, Eduard, Szoecs, Helene Wagner. vegan: Community
   Ecology Package. R package version 2.5-6 ed, 2019.
- Venables WNR, B. D. Modern Applied Statistics with S. Volume Fourth Edition. New York: Springer, 2002.
- 691 35. Pinheiro J BD, DebRoy S, Sarkar D, R Core Team, nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-144 ed, 2020.
- Vandeputte D, Kathagen G, D'hoe K, et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature 2017;551:507-511.

- Bradley PH, Pollard KS. Proteobacteria explain significant functional variability in the human gut microbiome. Microbiome 2017;5:36-36.
- 697 38. Yassour M, Vatanen T, Siljander H, et al. Natural history of the infant gut 698 microbiome and impact of antibiotic treatment on bacterial strain diversity and 699 stability. Sci Transl Med 2016;8:343ra81.
- 700 39. Obermajer T, Grabnar I, Benedik E, et al. Microbes in Infant Gut Development:
   701 Placing Abundance Within Environmental, Clinical and Growth Parameters. Sci
   702 Rep 2017;7:11230.
- 703 40. Stoddard SF, Smith BJ, Hein R, et al. rrnDB: improved tools for interpreting
   704 rRNA gene abundance in bacteria and archaea and a new foundation for future
   705 development. Nucleic Acids Res 2015;43:D593-8.
- 706 41. Selma-Royo M, Calatayud Arroyo M, García-Mantrana I, et al. Perinatal 707 environment shapes microbiota colonization and infant growth: impact on host 708 response and intestinal function. Microbiome 2020;8:167.
- Martin R, Makino H, Cetinyurek Yavuz A, et al. Early-Life Events, Including
   Mode of Delivery and Type of Feeding, Siblings and Gender, Shape the
   Developing Gut Microbiota. PloS one 2016;11:e0158498-e0158498.
- 43. Korpela K, Helve O, Kolho KL, et al. Maternal Fecal Microbiota
   Transplantation in Cesarean-Born Infants Rapidly Restores Normal Gut
   Microbial Development: A Proof-of-Concept Study. Cell 2020;183:324-334.e5.
- 715 44. Nogacka AM, Salazar N, Arboleya S, et al. Early microbiota, antibiotics and health. Cell Mol Life Sci 2018;75:83-91.
- Kamal SS, Hyldig N, Krych Ł, et al. Impact of Early Exposure to Cefuroxime
   on the Composition of the Gut Microbiota in Infants Following Cesarean
   Delivery. The Journal of Pediatrics 2019;210:99-105.e2.
- Korpela K, Costea P, Coelho LP, et al. Selective maternal seeding and
   environment shape the human gut microbiome. Genome research 2018;28:561 568.
- Azad MB, Konya T, Persaud RR, et al. Impact of maternal intrapartum
   antibiotics, method of birth and breastfeeding on gut microbiota during the first
   year of life: a prospective cohort study. Bjog 2016;123:983-93.
- 48. Imoto N, Kano C, Aoyagi Y, et al. Administration of β-lactam antibiotics and delivery method correlate with intestinal abundances of Bifidobacteria and Bacteroides in early infancy, in Japan. Scientific reports 2021;11:6231-6231.
- 729 49. Chen YY, Zhao X, Moeder W, et al. Impact of Maternal Intrapartum
   730 Antibiotics, and Caesarean Section with and without Labour on Bifidobacterium
   731 and Other Infant Gut Microbiota. Microorganisms 2021;9:1847.
- 732 50. Ainonen S, Tejesvi MV, Mahmud MR, et al. Antibiotics at birth and later antibiotic courses: effects on gut microbiota. Pediatric Research 2021.
- Aloisio I, Mazzola G, Corvaglia LT, et al. Influence of intrapartum antibiotic prophylaxis against group B Streptococcus on the early newborn gut composition and evaluation of the anti-Streptococcus activity of Bifidobacterium strains. Appl Microbiol Biotechnol 2014;98:6051-60.
- 52. Sprockett D, Fukami T, Relman DA. Role of priority effects in the early-life
   assembly of the gut microbiota. Nat Rev Gastroenterol Hepatol 2018;15:197 205.
- 741 53. Salvatore S, Baldassarre ME, Di Mauro A, et al. Neonatal Antibiotics and
   742 Prematurity Are Associated with an Increased Risk of Functional

- Gastrointestinal Disorders in the First Year of Life. The Journal of Pediatrics 2019;212:44-51.
- 745 54. de Weerth C, Fuentes S, Puylaert P, et al. Intestinal microbiota of infants with colic: development and specific signatures. Pediatrics 2013;131:e550-8.
- 747 55. Pärtty A, Kalliomäki M, Endo A, et al. Compositional Development of
   748 Bifidobacterium and Lactobacillus Microbiota Is Linked with Crying and
   749 Fussing in Early Infancy. PLoS One 2012;7.
- 750
   751
   751
   752
   Pham VT, Lacroix C, Braegger CP, et al. Lactate-utilizing community is associated with gut microbiota dysbiosis in colicky infants. Scientific Reports (Nature Publisher Group) 2017;7:1-13.
- 753 57. Vandenplas Y, Hauser B, Salvatore S. Functional Gastrointestinal Disorders in
   754 Infancy: Impact on the Health of the Infant and Family. Pediatric
   755 gastroenterology, hepatology & nutrition 2019;22:207-216.
- 58. Lawson MAE, O'Neill IJ, Kujawska M, et al. Breast milk-derived human milk
   oligosaccharides promote Bifidobacterium interactions within a single
   ecosystem. The ISME Journal 2020;14:635-648.
- Marcobal A, Barboza M, Sonnenburg ED, et al. Bacteroides in the infant gut consume milk oligosaccharides via mucus-utilization pathways. Cell Host Microbe 2011;10:507-14.
- Ward RE, Niñonuevo M, Mills DA, et al. In vitro fermentation of breast milk
   oligosaccharides by Bifidobacterium infantis and Lactobacillus gasseri. Appl
   Environ Microbiol 2006;72:4497-9.
- 765 61. Coppa GV, Gabrielli O, Pierani P, et al. Changes in carbohydrate composition in human milk over 4 months of lactation. Pediatrics 1993;91:637-41.
- 767 62. Duar RM, Kyle D, Casaburi G. Colonization Resistance in the Infant Gut: The
   768 Role of B. infantis in Reducing pH and Preventing Pathogen Growth. High
   769 Throughput 2020;9.
- Henrick BM, Hutton AA, Palumbo MC, et al. Elevated Fecal pH Indicates a
   Profound Change in the Breastfed Infant Gut Microbiome Due to Reduction of
   <em&gt;Bifidobacterium&lt;/em&gt; over the Past Century. mSphere
   2018;3:e00041-18.
- Rutayisire E, Huang K, Liu Y, et al. The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants' life: a systematic review. BMC Gastroenterol 2016;16:86.
- Korpela K, Salonen A, Hickman B, et al. Fucosylated oligosaccharides in mother's milk alleviate the effects of caesarean birth on infant gut microbiota.
   Scientific Reports 2018;8:13757.
- Korpela K, Salonen A, Vepsäläinen O, et al. Probiotic supplementation restores
   normal microbiota composition and function in antibiotic-treated and in
   caesarean-born infants. Microbiome 2018;6:182.
- Gensollen T, Iyer SS, Kasper DL, et al. How colonization by microbiota in early life shapes the immune system. Science 2016;352:539-44.

Table 1 Faecal samples analysed per delivery group and age (relative data /absolute data).

	VD	VD-cep	VD-pen	CS-cep	CS-other
1 day	11/0	1/0	4/0	2/0	0/0
2 days	23/4	2/0	7/5	5/2	2/1
1 week	31/1	3/0	13/0	7/0	0/0
1 month	46/25	12/7	23/12	33/32	13/13
6 weeks	20/20	10/7	10/8	25/25	12/12
3 months	41/20	12/7	22/8	31/27	13/12
6 months	48/22	12/6	24/12	32/30	13/12
9 months	16/16	7/4	9/7	20/20	10/8
12 months	36/3	8/0	15/3	12/4	3/1

VD = vaginal delivery, cep = cephalosporin, pen = penicillin, CS = Caesarean section

Table 2 Intrapartum antibiotics and doses by delivery group among the 144 infants (relative data / absolute data).

Birth mode	antibiotic	1 dose	2 or more doses	Total count of infants
VD	penicillin	4/1	21/12	25/13
	cefuroxime	8/3	5/4	13/7
Elective CS	cefuroxime	13/12		13/12
	cephalexin	7/7		7/7
	clindamycin	1/1		1/1
	metronidazole	1/1		1/1
	not reported	1/1		1/1
Urgent CS	cefuroxime	10/10	1/1	11/11
_	cephalexin	3/3		3/3
	clindamycin	2/2	2/2	4/4
	penicillin		2/1	2/1
	combination	1/1	4/4	5/5

VD = vaginal delivery, CS = Caesarean section.

Figure 1 Temporal development of six most abundant bacterial classes in absolute (A) and relative (B) abundance in vaginally born infants not exposed to antibiotics. The lines show means with 50% confidence interval.

Figure 2 Principal coordinates analysis of the species-level absolute (A) and relative (B) abundances. Distances calculated based on Pearson correlations. The samples are coloured by treatment group and the mean component scores of the groups by age (weeks) presented by large circles.

Figure 3 Fold changes calculated using absolute abundances of bacterial families with at least one group significantly differing from the reference group (VD) in the taxon-wise comparisions between all delivery groups. VD: vaginal delivery without antibiotic, VD-cep: vaginal delivery with cephalosporin, VD-pen: vaginal delivery with penicillin, CS-cep: C-section with cephalosporin, CS-other: C-section with any other antibiotic; FC: fold change (cut-off at 5 and 0.001 for clarity); \*: P<0.05, \*\*: P<0.01, \*\*\*: P<0.001, in all cases FDR<0.1.

Figure 4 Parent-reported health outcomes at faecal sampling points from 1 to 6 by delivery group. \*: P < 0.05, \*\*: P < 0.01, \*\*\*: P < 0.001Figure 5. Associations between birth interventions, absolute abundances of bacteria, and GI symptoms at 4 weeks (a), 6 weeks (b), 12 weeks (c) and 24 weeks (d). The amount of variation explained by the bacteria shown is given as percentage. The models were selected based on Akaike information criterion (AIC). In some cases, the final model retained variables that were not statistically significant but contributed significantly to the model.







